Kirschbrown, Whitney P.
Wang, Bei
Nijem, Ihsan
Ohtsu, Atsushi
Hoff, Paulo M.
Shah, Manish A.
Shen, Lin
Kang, Yoon-Koo
Alsina, Maria
Girish, Sandhya
Garg, Amit http://orcid.org/0000-0002-4553-9216
Funding for this research was provided by:
F. Hoffmann-La Roche
Article History
Received: 18 January 2019
Accepted: 22 April 2019
First Online: 10 June 2019
Compliance with ethical standards
:
: All authors received support for third-party writing assistance for this manuscript, provided by F. Hoffmann-La Roche Ltd. Whitney Kirschbrown, Ihsan Nijem, Amit Garg, and Sandhya Girish are employees of Genentech, Inc., and hold stock in Roche Holding Ltd. Whitney Kirschbrown is an inventor on a pertuzumab-related filing. Bei Wang is an employee of Genentech, Inc. Atsushi Ohtsu has received research grants from BMS and honoraria from BMS, Ono, Chugai, and Taiho. Paulo M. Hoff has received research grants from Roche relating to the conduct of this study. Manish A. Shah discloses research funding paid to his institution from Boston Biomedical, Merck, and Roche. Lin Shen received non-financial support from Roche Pharmaceuticals Ltd. relating to the conduct of this study and a research grant from Hengrui Medicine Co. Ltd, indirectly related to this manuscript. Yoon-Koo Kang has received research grants from Roche, Daehwa and LSK Biopharma, and has received personal fees from Ono, BMS, Novartis, Lilly, Daehwa, and LSK Biopharma. Maria Alsina has performed an advisory role for BMS, Servier, and MSD, received research funding from Merck-Serono, and received speaker fees from MSD, BMS, Lilly, Roche, Amgen, and AstraZeneca.
: The study was conducted in accordance with the ethical standards established in the 1964 Declaration of Helsinki and its later amendments. The study was approved by the institutional review board of each study site, and all patients participating in the study provided informed consent before enrollment.